DO-BO

Are Primary Research Platforms Defining a New Era, Shrutya Bhalla?

In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must enable real strategic choices on pricing, access, launch sequencing, and evidence generation. This means moving from slow, static projects to continuous, platform‑driven, AI‑supported research, using AI for speed, automation and better hypotheses while keeping humans firmly in the lead for judgment, context and responsibility, and building research that is robust enough for MFN, new US tariffs, and fast‑changing global policy environments.

Shrutya also shares how new stakeholder research platforms like Mulya, and innovations such as Market Access 4.0 tools like mAxInsights, DO-Bo, Q-Bo and Wafle, are redefining how we run payer research: faster, more economical, and closer to real‑time decision needs. If you work in market access, pricing, Health Economics and Outcomes Research (HEOR) or commercialization, this episode is a must‑listen to understand where primary research is headed.

Related

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]